AZ goes Down Under for cancer conjugate deal

AstraZeneca ($AZN) has signed a deal with Australian company Starpharma Holdings. Under the terms of the agreement, AstraZeneca will test Starpharma drug-dendrimer conjugate molecules as potential anti-cancer agents. The precise molecules were not disclosed, but do not include docetaxel or dendrimer conjugates of docetaxel, according to Starpharma. Press release